Status:
ACTIVE_NOT_RECRUITING
A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Hypertrophic Cardiomyopathy
Eligibility:
All Genders
18+ years
Brief Summary
This real-world study will describe the demographic and clinical characteristics and mavacamten treatment of adult patients with obstructive hypertrophic cardiomyopathy who participated in the Bristol...
Eligibility Criteria
Inclusion
- Participants ≥18 years of age.
- Participants who have initiated mavacamten as part of routine clinical care, through the BMS-sponsored CAMZYOS Patient Support Program for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.
- Participants who consented to the use of their de-identified data, generated from information collected in the course of the program.
Exclusion
- • There are no exclusion criteria.
Key Trial Info
Start Date :
April 20 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 18 2025
Estimated Enrollment :
685 Patients enrolled
Trial Details
Trial ID
NCT06549608
Start Date
April 20 2024
End Date
April 18 2025
Last Update
February 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Paul's Hospital
Vancouver, British Columbia, Canada